Department of Surgery, Brooke Army Medical Center, 3551 Roger Brooke Dr., Ft. Sam Houston, TX, 78234, USA.
Department of Pathology, Brooke Army Medical Center, 3551 Roger Brooke Dr., Ft. Sam Houston, TX, 78234, USA.
Cancer Immunol Immunother. 2021 May;70(5):1465-1474. doi: 10.1007/s00262-020-02784-5. Epub 2020 Nov 12.
Colorectal cancer (CRC) tumor microenvironment (TME) characteristics, such as tumor infiltrating lymphocyte (TIL) densities and PD-L1 status, are predictive of recurrence, disease-free survival, and overall survival. In many malignancies, TME characteristics are also predictive of response to immunotherapy. As window of opportunity studies using neoadjuvant immunotherapy become more common and treatment guidelines incorporate TME features, accurate assessment of the pre-treatment TME using the biopsy specimen is critical. However, no study has thoroughly evaluated the correlation between the TMEs of the biopsy and resection specimens.
We conducted a retrospective analysis of patients with stage I-III CRC with matched biopsy and resection specimens. CD3+, CD4+, CD8+, and FoxP3+ lymphocyte populations at the center of tumor (CT) and invasive margin (IM) and tumor PD-L1 status in the biopsy and resection specimens were evaluated. TIL populations were compared using Mann-Whitney U tests or Student's t tests and correlated using Pearson r.
CD3+ and CD4+ densities were significantly higher in the CT of the biopsy relative to the resection specimen Comparing biopsy and resection specimens, no TIL population at either the CT or IM had a correlation coefficient > 0.5. Determining PD-L1 status based on biopsy tissue resulted in a sensitivity of 37.1%, specificity of 81.4%, and accuracy of 61.5%.
These findings demonstrate significant discordance between the TME of the biopsy and resection specimens. Caution should be used when basing treatment decisions on pre-treatment endoscopic biopsy findings and when interpreting changes in the TME between pre-treatment biopsy and resection specimens after neoadjuvant therapy.
结直肠癌(CRC)肿瘤微环境(TME)特征,如肿瘤浸润淋巴细胞(TIL)密度和 PD-L1 状态,可预测复发、无病生存和总生存。在许多恶性肿瘤中,TME 特征也可预测免疫治疗的反应。随着新辅助免疫治疗的机会窗口研究变得越来越普遍,并且治疗指南纳入了 TME 特征,使用活检标本准确评估治疗前 TME 变得至关重要。然而,尚无研究彻底评估活检和切除标本的 TME 之间的相关性。
我们对具有匹配活检和切除标本的 I-III 期 CRC 患者进行了回顾性分析。评估了肿瘤中心(CT)和浸润边缘(IM)活检和切除标本中的 CD3+、CD4+、CD8+和 FoxP3+淋巴细胞群以及肿瘤 PD-L1 状态。使用 Mann-Whitney U 检验或学生 t 检验比较 TIL 群体,并使用 Pearson r 进行相关性分析。
与切除标本相比,活检 CT 处的 CD3+和 CD4+密度显著更高。比较活检和切除标本,CT 或 IM 处的任何 TIL 群体均无相关系数>0.5。基于活检组织确定 PD-L1 状态的敏感性为 37.1%,特异性为 81.4%,准确性为 61.5%。
这些发现表明活检和切除标本的 TME 之间存在显著差异。在基于治疗前内镜活检结果做出治疗决策时以及在新辅助治疗前后治疗前活检和切除标本之间的 TME 变化时应谨慎。